Stay updated with breaking news from Daniel Passeri. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
BOSTON, April 08, 2024 -- Cue Biopharma, Inc. , a clinical-stage biopharmaceutical company developing a novel class of therapeutic biologics to selectively modulate disease-specific T cells, today...
Operator: Good afternoon, ladies and gentlemen, and welcome to the Cue Biopharma Third Quarter 2023 Earnings Call. At this time, all lines are in listen-only mode.
Cue Biopharma, Inc. (NASDAQ:CUE) Q3 2023 Earnings Call Transcript November 11, 2023 Operator: Good afternoon, ladies and gentlemen, and welcome to the Cue Biopharma Third Quarter 2023 Earnings Call. At this time, all lines are in listen-only mode. Following the presentation, we will conduct a question-and-answer session. [Operator Instructions] As a reminder, this call is […]
Completed enrollment of patient expansion cohort of 20 patients at the RP2D of 4 mg/kg in combination with KEYTRUDA® (pembrolizumab) in first line...
BOSTON, May 09, 2023 -- Cue Biopharma, Inc. , a clinical-stage biopharmaceutical company developing a novel class of injectable biologics to selectively engage and modulate disease-specific T... | May 9, 2023